Revised version,11Jan2023. MChu

### **RESEARCH ARTICLE**

# TITLE: Specimen sharing for epidemic preparedness: building a local-to-global virtual biorepository framework

Key words: virtual biorepository system, framework for specimen access, diagnostics, research, preparedness, governance, global public goods

Authors:

Judith Giri<sup>1&</sup>, Laura Pezzi<sup>2^</sup>, Rodrigo Cachay<sup>3^</sup>, Rosa Margarita Gèlvez Ramirez<sup>4^</sup>, Adirana Tami<sup>#5^</sup>, Sarah Bethencourt<sup>6^</sup>, Anylea Lozano<sup>7^</sup>, Julia Poje<sup>1^</sup>, Thomas Jaenisch<sup>1&</sup>, May Chu<sup>1&\*</sup>

<sup>1</sup>Center for Global Health, Colorado School of Public Health, Anschutz Medical Center, Aurora, Colorado, USA

judith.giri@outlook.com, thomas.jaenisch@cuanschutz.edu, may.chu@cuanschutz.edu

<sup>2</sup> Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207), Marseille, France. <u>laura.pezzi@univ-amu.fr</u>

<sup>3</sup> Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Av. Honorio Delgado 430, San Martín de Porres | Lima, Perú <u>rodrigo.cachay.f@upch.pe</u>

<sup>4</sup>Centro de Atención y Diagnóstico de Enfemedades Infecciosas-CDI, Fundación INFOVIDA, Bucaramanga, Colombia. <u>margarita.gelvez@hotmail.com</u>

<sup>#</sup>Current Address: Department of Medical Microbiology & Infection Prevention, University Medical Center Groningen, Netherlands.<u>a.tami@umcg.nl</u>

<sup>5</sup>Facultad de Ciencias de la Salud, Departamento de Parasitología, Universidad de Carabobo, Valencia, Carabobo, Venezuela

Revised version,11Jan2023. MChu

<sup>6</sup> Departamento de Estudios Clínicos-Department of clinical studies, Venezuela. <u>tatybethen@gmail.com</u>

<sup>7</sup>Centro de Investigaciones Epidemiológicas, Universidad Industrial de Santander. Bucamaranga, Colombia. <u>anyelalozano814@gmail.com</u>

\*Corresponding author Email: <u>may.chu@cuanschutz.edu</u> (MC)

<sup>&</sup>These authors contributed equally to this work.

<sup>^</sup>These authors also contributed equally to this work.

Revised version,11Jan2023. MChu

#### 1 Abstract

We present a framework for a federated, virtual biorepository system (VBS) with locally 2 collected and maintained specimens, based on a 'global goods' model and principles of 3 equitable access and benefit sharing. The VBS is intended to facilitate timely access to 4 5 biological specimens and associated data for outbreak-prone infectious diseases to accelerate the development and evaluation of diagnostics, assess vaccine efficacy, and to 6 support surveillance and research needs. The VBS is aimed to be aligned with the WHO 7 BioHub and other specimen sharing efforts as a force multiplier to meet the needs of 8 9 strengthening global tools for countering epidemics. The purpose of our research is to lay the basis of the collaboration, management and principles of equitable sharing focused on 10 low- and middle-income country partners. Here we report on surveys and interviews 11 undertaken with biorepository-interested parties to better understand needs and barriers for 12 specimen access and share examples from the ZIKAlliance partnership on the governance 13 and operations of locally organized biorepositories. 14

Revised version,11Jan2023. MChu

# Introduction

The continuing and evolving emerging epidemics - Ebola, Zika and COVID-19 to name only 15 a few - highlight the need for timely, transparent and efficient access to quality, annotated 16 specimens to drive research, development of new diagnostics and treatments, disease 17 surveillance, and to measure vaccine efficacy on a global scale. Accessing quality 18 specimens has been largely driven by pathogen-specific needs and related research 19 interests, with little consideration to the broader sharing of those specimens or collections. 20 Trusted infrastructure and specimen sharing mechanisms need to be in place to support the 21 needs of emergent outbreak responses. Without a supportive infrastructure, equitable and 22 ethical sharing of specimens can become complicated, with layers of barriers that lead to 23 prolonged and stressful processes, blunting the best intentions to guickly respond to public 24 health emergencies [1-6]. 25 Biorepositories (biobanks) retain and collect specimens (samples) as a fundamental 26 27 resource for advancing research and serve as essential infrastructure for responsible and ethical specimen management. Biorepositories are also rapidly evolving and gaining more 28

29 prominence in the data-driven health research arena [7-10]. Great strides have been made

30 from the hand labeled small collection in an investigator's freezer to the professionally

31 managed institutional facilities, with quality management systems based on best practices

32 [11] and accreditation standards- ISO 20387;20189(E) Biotechnology-Biobanking standards

33 (https://www.iso.org/obp/ui/#iso:std:iso:20387:ed-1:v1:en) supported by robust inventory

34 systems and associated clinical data. Most large-scale biorepositories have been established

to meet specimens needs for non-communicable diseases like cancer or genetic disorders

and, more recently, to benefit personalized medicine [9,11,12]. Large population-based

37 public health and clinical biorepositories have also been established such as the United

38 Kingdom Biobank (<u>https://www.ukbiobank.ac.uk/</u>), the National Health and Nutrition

39 Examination Survey (<u>https://www.cdc.gov/nchs/nhanes/biospecimens/biospecimens.htm</u>),

40 the National Cancer Institute (<u>https://www.cancer.gov/research/infrastructure</u>) as well as

biobank hubs such as the German Biobank Node [13]. The COVID-19 pandemic has led to a

42 proliferation of collections both in existing and COVID-19-centric biorepositories (PATH,

Revised version,11Jan2023. MChu

- 43 https://www.path.org/programs/diagnostics/washington-covid-19-biorepository/ [14-16]. Yet,
- 44 despite the existence of these developments there is still room for additional collections as
- 45 these do not represent the diverse range of geography, ecozones, and demographics
- <sup>46</sup> needed to support emerging infectious disease research response efforts. The need for
- 47 broader specimen collections for (emerging) infectious diseases, representative of diverse
- 48 populations, especially from LMIC, remains an unmet need and even given recent
- 49 investments during COVID-19, a transparent sharing system has not been fully realized
- 50 [5,6,14,17].
- 51 A major challenge remains the coordination of biorepositories and collections in different
- 52 geographic areas and overcoming obstacles for access. A few successful models such as
- the Foundation for Innovative Diagnostics (FIND) DxConnect (<u>https://www.finddx.org/wp-</u>
- 54 <u>content/uploads/2022/12/20211202\_fac\_specimen\_bank\_VF\_EN.pdf</u>) and the European
- 55 Viral Archive-Global provides a trusted broker role in accessing virus strains, molecular
- targets, virus components and cell lines [2,18] and in this paper, the ZIKAlliance network of
- 57 local biorepositories all showing that there are communities of practice willing to share and
- 58 have needs to access timely, quality specimens.
- A frequently invoked barrier is the benefit sharing requirement of the Convention for 59 Biological Diversity's Nagoya protocol (Protocol, The Nagoya Protocol on Access and 60 Benefit-sharing (cbd.int)). The Nagoya protocol mandates signatories to the Protocol to 61 comply with respective national requirements for benefits to be equitable and fairly shared if 62 materials from that country contributed to the development of products such as diagnostic 63 tests, vaccines, or therapeutics. National signatories have adopted differing interpretations of 64 the Protocol which has become potential barriers for access to specimens [19]. The full 65 impact and benefits enshrined in the Protocol remains a work in progress and is being 66 actively addressed by the WHO Biohub effort. 67
- 68 A serious challenge in sourcing specimens across countries and institutions is the inherent
- 69 heterogeneity of methods of collection, characterization and handling of specimens and data,
- and the difficulty this poses for users regarding the quality and integrity of the specimens.
- 71 This is not surprising because maintenance of biorepositories is typically an unfunded
- 72 mandate for a clinic or laboratory. Without active efforts to standardize, it is not surprising

Revised version,11Jan2023. MChu

that infectious disease biorepositories are fragmented and pose challenges to the
stakeholder community trying to create access to specimens. Fortunately, we have been
aware of several functional efforts which can serve as models to guide our approaches for a
harmonized VBS framework.

77 The abundance of specimens during the COVID-19 pandemic, unlike previous situations in outbreaks where competition for a limited number of specimens was the rule, provided a 78 good opportunity to examine existing gaps for specimen collection, their use, and sharing 79 mechanisms [1,5,16]. We identified that there are many untapped and interested sites that 80 could be contributors and users of specimens, but lack a holistic and more cohesive 81 82 approach to identify and tackle the barriers to receive the benefits of sharing. An approach, centered on participation of low-and-middle income countries (LMIC), who often are at the 83 84 center of new public health threats or emerging zoonotic hot zones, could prove pivotal in enabling LMIC to lead collecting and managing specimens for broader sharing [3,20,21]. 85 86 Therefore, we sought to seek input from a broad group with interest in accessing/providing specimens, especially for serological diagnostics, to examine how to best provide practical 87 solutions that take advantage of existing collections rather than investing in building large 88 new biorepository facilities. We initiated a series of workshops, and while heavily interrupted 89 90 by the emergence and spread of COVID-19, the pandemic also provided an opportunity to engage many more who are interested in specimen sharing. 91

The efforts leading up to this manuscript were initiated at a workshop at ASTMH in 2019, coconvened by Center for Global Health (CGH) at the Colorado School of Public Health and

FIND as an outcome of the 2016 Zika virus public health emergency. We have subsequently
 organized virtual workshops hosted by the Global Health Network (TGHN;

96 https://globalbiorepository.tghn.org/) and initiated a survey and interviews with these goals in

97 mind: to identify the current barriers to specimens sharing and unmet needs of various

- stakeholders; and initiate discussion about proposed distributed, locally-managed virtual
- <sup>99</sup> biorepository system (VBS) as a solution to meeting key challenges.

We based our questions in the survey and the interviews on a vision for a VBS characterized by principles of equitable, transparent access to specimens for the 'global good', and at the same time responding to the needs of diverse stakeholders. We focused on diseases caused

Revised version,11Jan2023. MChu

103 by pathogens with outbreak potential and placed emphasis on specimens for development of

- diagnostics and research. In our survey and interviews we asked participants what their view
- might be for a sustainable infrastructure focused at the LMIC level that provides benefits to
- 106 diverse specimen consumers and providers.
- 107 We intend to use a grassroots approach to developing a VBS that will support local
- 108 governance and stewardship of specimens. For that reason, we sought input from local
- 109 decision-making and governance structures in LMICs regarding the sharing of biological
- material, incorporating longstanding collaborative relationships of the authors (e.g., within the
- 111 Reconciliation of Cohort Data for Infectious Diseases (ReCoDID), <u>www.recodid.eu</u>; and
- 112 ZIKAlliance consortia, <u>https://zikalliance.tghn.org/</u> and AEDES Network,
- 113 <u>https://www.redaedes.org/</u>). Since 2021, we have joined forces with the Center for Research
- in Emerging Infectious Disease (CREID) Coordinating Center (https://creid-
- 115 <u>network.org/coordinating-center</u>) to guide the activities of the VBS.
- 116

# 117 Methods

## 118 Participation and privacy policy

119 Participants included in our workshops and survey demonstrate a broad representation of 120 individuals who had expressed interest in biorepository activities (either through contact with

- 121 our website hosted by the Global Health Network or from individuals who volunteered to join
- the discussions on a personal interest basis. Participants were informed that they retained
- the right to withdraw without penalty and the collected data would be de-identified and
- reported in aggregate form following the research-ethics guidelines of the American
- 125 Psychological Society research-ethics guidelines (<u>https://www.apa.org/ethics/code/ethics-</u>
- 126 <u>code-2017.pdf</u>). The registered IRB protocol waiver is #23-0079 from the University of
- 127 Colorado-Anschutz.
- 128

# 129 **Consultative workshops and recruitment of participants**

#### Revised version,11Jan2023. MChu

Workshops were conducted to identify what the challenges and needs might be to build a 130 durable grassroots system to access specimens. Three workshops, in person (2019) and 131 132 online conferences (2020 and 2021) were convened to identify, evolve and fine-tune the tasks for the VBS. Invitations were extended to those individuals and/or representatives of 133 agencies and entities who had joined previous biorepository activities, to those identified 134 through publications as well as those who had expressed interest through TGHN website. 135 The scope began by looking at the challenges encountered during the ZIKV epidemic in 136 South America and the Caribbean. Then the scope was extended to include discussion of 137 the COVID-19 pandemic and outbreak-prone diseases in the second and third workshops to 138 explore potential benefits on for both the sample contributor as well as the user or 'client' 139 side. 140

141

#### 142 Survey on benefits in participating in a VBS

A self-administered 10-question qualitative survey (Supporting Information, SI; Table 1) was
 created on the SurveyMonkey platform for the participants. The survey was accessed by
 email or website (<u>https://globalbiorepository.tghn.org/</u>) between December 2020 through
 January 2022. Data analysis was finalized in December 2022.

147

#### 148 Interviews to assess needs and barriers to accessing specimens

Video-conference interviews were conducted jointly by 2 members of the study team (JG and 149 MC) and recorded with the consent of the interviewees. We targeted potential users of well-150 characterized specimens, including commercial as well as academic entities. Commercial 151 152 users consisted of diagnostics industry companies that represented both small in vitro diagnostics (IVD) products <10 and mid-size to larger (with IVD products > 10) operations 153 [22]. We also interviewed not-for-profit commercial, research and academic/government 154 entities with regard to their need and use of biological samples. Our questions were based 155 on their respective strategies in developing diagnostic tests and reference controls and how 156 157 they would acquire materials for developing an IVD. Interviewees were encouraged to provide additional feedback about specific hurdles they encountered sourcing specimens. 158

Revised version,11Jan2023. MChu

- 159 The interviews lasted on average from 40 to 60 minutes and responses were compared and 160 tabulated for analysis. The complete seven question survey is in SI, Table 2.
- 161

#### 162 Local biorepository governance structures

163 We also conducted interviews with research teams from the ZIKAlliance consortium [21] including: (a) the Industrial University of Santander, Bucamaranga, Colombia; (b) the 164 University of Carabobo, Valencia, Venezuela; and (c) Cayetano Heredia University in Lima, 165 Peru as case examples of locally governed biorepositories. Each of these entities had 166 established human subject ethics approved biorepositories in response to Zika virus 167 168 research needs with ability to share samples for advancing research and as reference materials. In the case of Colombia, they already had established the AEDES Network that 169 170 included sample sharing within the network members. Their collective experiences are used to illustrate their biorepository decision-making governance and operational structures and 171 172 how this infrastructure may set as examples of locally managed sample sharing mechanisms. 173

174

#### 175 **Results**

#### 176 Benefits survey

#### 177 Characteristics of survey respondents

Forty-seven respondents completed the survey, and their replies were aggregated and 178 analyzed. Respondents logged into the survey from Africa (n=15), North America (n=10) 179 Europe (n=9), Latin America (n=9) and 5 were from the Asia-Pacific region (Fig 1). They 180 represented a variety of organizations from research institutions (n=23), not-for-profit or 181 government institutions (n=22), public health and clinical laboratories (n=9), biorepositories 182 (n=5) and commercial diagnostics laboratories (n=3); a few respondents (n=4) did not identify 183 their affiliation. Respondents were able to select more than one category, for example both 184 research and government institution. The participants also represented a broad group of 185 186 stakeholders with a variety of roles, including principal investigators, public health officials, institution leaders, and laboratory or biorepository managers. 187

Revised version,11Jan2023. MChu

#### 188

#### 189 Figure 1: The geographic location of survey respondents

190

#### 191 Benefits of the VBS

Embedded in our 10-question survey (SI, Table 1) were 3 questions aimed specifically at understanding what respondents considered to be the key benefits for participating in a VBS. Survey respondents could choose all that applied to them from a list of potential benefits and rank their importance. These questions were: (a) which planned VBS benefits would be most important to you/your institution? (Q4), (b) which VBS support functions would be most valuable to your current biorepository or collection? (Q5) and (c) which additional resource would allow you to participate in the VBS (Q6).

The most important benefits for investigators or their institutions that ranked over 50% in
favor of were: (a) the opportunity to network and collaborate with international partners
(38/47, 81%), (b) capacity building for infectious disease specimen resources (35/47, 74%),
(c) career growth and training opportunities (28/47, 60%), (d) greater visibility and utilization
of specimens (26/47, 55%) and (e) additional funding opportunities 25/47, 53%) as shown in
Table 1.

When survey respondents were asked to identify which features/functions of the VBS would 205 206 be of highest benefit to their current or future local biorepository operations (Table 1), the most often selected functions were (a) the availability of standardized procedures and 207 processes including Standard Operating Procedures (SOPs), guality standards, templates for 208 Material Transfer Agreements (MTAs) and for consent procedures, (33/47, 70%); and (b) the 209 210 coordination of logistics for accessing and distributing specimen, such as communications, review of requests and assistance with legal and ethical issues (30/47, 64%) with (c) 211 212 inclusion in a catalog and directory and laboratory informatics tools and support being equally selected as valuable features by 24/47 (51%). The feature of a catalogue and 213 214 directory was the top of list of valuable VBS function for diagnostics developers, especially smaller companies interviewed, as described in the next section. 215

Revised version,11Jan2023. MChu

order of preference				
FOR INVESTIGATORS AND THEIR INSTITUTIONS	N (%)	FOR CURRENT OR FUTURE BIOREPOSITORY OPERATIONAL NEEDS	N (%)	
Local and international networking and collaboration	38 (81)	Standardized procedures and processes and templates (SOP, quality, MTA, consent)	33 (70)	
Capacity building for infectious disease biorepositories	35 (75)	Coordination of access and distribution of specimens (communication, review of requests, logistics and legal/ethical)	30 (64)	
Career growth and training opportunities	28 (60)	Inclusion in online catalog or directory specimen resources	24 (51)	
New funding opportunities	25 (53)	Laboratory Informatics tools and support	24 (51)	
Reputation as trusted source of Specimens	22 (47)	Access to biorepository expertise/collections management	22 (47)	
Supporting test developers and industry	20 (43)	Coordination of laboratory services	13 (28)	
Authorship on publications	18 (38)			
Other comments	4(8)	Other comments	5 (11)	

Table 1. Virtual biorepository functions and services of greatest benefit listed by order of preference

216

217 In addition to the direct responses to the survey questions, an open comments section offered an opportunity to suggest additional desirable benefits provided by the VBS that were not 218 included in the questions. The comments suggested that the VBS could: (a) serve as forum 219 for sharing successful problem-solving approaches (e.g., legal issues), (b) support start-up of 220 new biorepositories, (c) promote research and development capacity for preparedness in 221 LMICs, and (d) ensure proper attribution for specimen providers. It was also recommended 222 that the VBS should strive for a governance framework in which all partners are treated as 223 equal members. In our questionnaire, we also asked what additional resources the 224

#### Revised version,11Jan2023. MChu

investigators or institutions may need to participate in the VBS. Only 42/47 responded to this question and for the majority they needed all the resources while others were more explicit in needing expertise in biorepository/collections management, informatics support and tools, equipment and maintenance, staff and facility improvements. These results would suggest that the need for resources goes beyond expected financial needs and reflects specific needs for the operation of the VBS.

231

#### 232 Barriers to sample sharing

A frequently invoked barrier for sharing samples across borders is a party's compliance with 233 the benefit sharing requirement of the Nagoya Protocol (NP). In Q7, respondents were asked 234 whether their country had any policies in accordance with the NP and whether it would prevent 235 them from contributing samples under the VBS. An interesting, but not surprising result was 236 that more than half of the responses (53%, 25 out of 47) indicated lack of familiarity with their 237 own country's regulations regarding the NP and the respective impact on sample sharing. 238 Respondents from countries with specific policies in accordance with the NP were asked to 239 elaborate whether the rules would prevent sharing outside the country. Some (19%, n=9)240 241 indicated that sharing was possible with approval from appropriate authoritative officials, such as their respective Ministries of Health. When international sharing was restricted, some 242 believed they could still participate and use their local specimens to test in-country, if reagents 243 or kits were provided. 244

245

#### 246 Other findings

We asked respondents about the feasibility of contributing to the VBS a set of qualified
specimens from their COVID-19 specimen collections to be used for creating evaluation
panels and 16 /40 of the responses (40%) indicated that they could provide such specimens.
We plan to follow up on this important question to explore whether the VBS could provide
specimen panels as a service. Several additional items for follow up were indicated in
comments (SI Table 1, Q10) including: (a) barriers to sharing such as shipping of specimens;
(b) recommendations for a successful partnership to be based on equity, respect and credit

Revised version,11Jan2023. MChu

- for contribution, (c) support for a VBS as a catalyst for research collaborations and, (d) the
- benefit of the VBS providing access to biorepository expertise.
- Finally, 40/47 respondents replied via comments to Q8 (SI Table 1) which asked them if they
- would be inclined to participate in a VBS and why they would join: 29/40 indicated they would
- join and the reasons were about samples, research, networking and an opportunity for
- benefits and for research affirming the choices in Q4-Q6 (SI Table 1).
- 260

# Interview results with consumers and providers: identifying unmet needs and barriers to access

263 Characteristics of interviewees

We specifically invited representative organizations with different perspectives and needs for detailed interviews: (a) developers of in vitro diagnostics with differing market sizes and (b) organizations providing specimens and related services, reference sample providers and managers of networks of collections.

268

A total of 11 interviews were conducted, We were able to Interview 4 small companies and 2 large/midsize companies that marketed their products globally. For analysis, we made two groups: (a) 4 small companies and 2 large/midsize for-profit enterprises with global markets and, (b) 5 not-for-profit enterprises, with a company that provided external quality assessment samples and those that were academic but government supported or government organizations. Despite the small number of interviewees, we were able to capture a wide range of organizations that provided us key insights.

276

## 277 Gaps and barriers for access to specimens

Among those interviewed, we found notable differences in the priority of concerns among the organizations with some common gaps or barriers when we compared their replies, summarized in Table 2.

281

#### Table 2. Common gaps and barriers of high concern for access to specimens

Revised version,11Jan2023. MChu

- a) Timely access to characterized high quality specimens
- b) Availability of specimen types needed for pathogen detection and test development; longitudinal collections and specimens collected at different times in an outbreak (before, during and after)
- c) Access to reliable and complete accompanying information (clinical data; specimen handling conditions)
- d) Need for sample panels and reference materials for quality assessment and validation
- 282

A detailed summary of the interview results is included in the SI Table 2, and demonstrates the common concerns as well as differences in the types of barriers and hurdles of highest concern for different types of organization interviewed. Availability of some specimen types both in the context of COVID-19, but especially for the previous outbreaks (limited geographically, seasonally, recurrence, etc.) was a universally recognized concern by all interviewees.

289

290 Some differences in ranking of the barriers were also evident from the interviews (SI Table 2), depending on the type of organization represented. For commercial IVD developers, a 291 292 comparison of larger vs small IVD developers indicated that for smaller companies identifying 293 reliable trusted sourcing of specimens was a very high priority for accelerating time to development and approval of new diagnostics. Interviews indicated that such companies 294 need to identify and negotiate with new sources of specimens for each new pathogen or 295 296 obtain specimens from commercial sources, while larger companies are more likely to have 297 long-standing collaborations with existing legal agreements. Related to sourcing was also access to reliable and sufficient data to meet regulatory requirements, as such data often is 298 inadequate for commercially acquired specimens and of convenient use of left-over 299 specimens whose control and oversight are not strictly managed. Data access restrictions, 300 301 especially in European counties, due to privacy rules may also impact access for all specimen users. Cost of specimens was also cited as a significant financial burden. These 302 issues affected all types of organizations but appeared to disproportionately impact small 303 304 companies and was more of a concern early in outbreaks resulting in considerable delays and lost opportunity for product development. 305

#### Revised version,11Jan2023. MChu

Organizations that work in the international sphere, primarily the not-for-profit organizations 307 that broker specimens for research and commercial and other entities, identified the Nagova 308 309 Protocol and related policies as the greatest barrier to access. They also expressed concern about the complexity and disparity in regulations between countries regarding export and 310 import of biospecimens and biosafety/biosecurity, that greatly impact efficient timely sharing 311 of specimens. Lack of trust was identified as important barrier for accessing specimens from 312 LMICs, including ethical concerns about appropriate use of specimens and a need for 313 greater awareness and investment in capacity building, training and emphasis on benefits for 314 partners from LMICs. This group also provided specific recommendations regarding features 315 of the VB that in their experience would meet the needs of various stakeholders (Table 3). 316 specifically these recommendations aimed to reduce the complexities around sample access 317 318 and specimen sharing under an operational structure to maintain guality and confidence in the materials to be accessed. 319

320

#### Table 3. Recommendations regarding features of a VBS

- a) Setting criteria for specimen and data quality that are deemed appropriate for inclusion into the VBS, with a potential grading to indicate fit for different uses
- b) Offering access to software to some users as needed to facilitate data sharing and resolve the hurdles created by use of disparate platforms and applications
- c) Standardizing of MTAs and negotiations to facilitate sharing and to enable agile responses in cases of public health emergencies
- d) Emphasis on quality to including not only specimen and data but also biorepository operations, such as standards for managing and preserving specimens
- e) Facilitation of access with a simplified review process by the VBS consortium
- f) Building biobanking capacity and trust in LMICs to enable equitable access to specimens and benefits

321

#### 322 Local governance models to inform the VBS framework

- 323 Here we describe locally-managed sample sharing model to inform how VBS could be
- 324 structured. During the Zika epidemic in South America (2016), ZIKAlliance partner
- institutions developed a common governance structure for local sample sharing to facilitate
- and to provide access to samples for research studies (Figure 2). The oversight research

#### Revised version,11Jan2023. MChu

plan and overarching ethics are determined in the ZIKAlliance framework and at each site, 327 with the decision and access to specimens residing with the local principal investigator (PI) 328 329 and the local Selection Panel (SP). Samples for sharing are listed in the public-facing catalogue with requests made through the local PI or leadership team and then reviewed by 330 the SP for its ethical intended use and research value. When a request is approved, the PI 331 the forwards it for to the next level to the regulator, which in Venezuela and Colombia is the 332 Ministry of Health and Social Protection and in Peru the Ministry of Health (SI Figures 1 A-C). 333 In a specific case of sample transfer from Colombia to France within ZIKAlliance, a submitted 334 request obtained the requisite local IRB approval with the appropriate scientific justification 335 for the transfer of the samples - namely in this case that the inclusion of a new molecular test 336 to be conducted in a central laboratory in alignment with the primary objectives of the 337 ZIKAlliance study. So following local approval, the sample transfer was then submitted for 338 permission to share with the Ministry of Health and Social Protection of Colombia 339 (https://www.minsalud.gov.co/Paginas/default.aspx) based on the Resolution 8430 of 1993 340 and Article 5 of the Resolution 3823 of 1997. The approval process, from time of request to 341 342 the PI can conclude within 1-2 months with official notification from the Ministry of Health to the PI. 343

Another example linked to this effort is the AEDES network in Colombia, where a Scientific Management Committee is responsible for coordinating the interaction and monitoring the progress of the technical, scientific and institutional strengthening components of the network in accordance with its Scientific Advisory Board and their Institutional Review Board or Ethics Committee.

In most of these projects, a publicly shared catalogue of the biological specimens is envisaged as the starting point (Figure 2) and the processes developed in the governance structure, allowed for a careful, thoughtful process at the hand of the local PI for sharing samples. This effort also then allows for recruitment and replenishment of samples. A future challenge beyond ZIKAlliance will be the availability of funds and scientific resolve to maintain this system.

355

356 Figure 2. Governance structure of the ZIKAlliance local biorepositories

Revised version,11Jan2023. MChu

357

## 358 **Discussion**

#### 359 Benefits survey results and its implications

Overall, our results show that networking opportunities and capacity building for infectious disease biorepositories were considered of high importance, as confirmed also in the open comments section of the survey. The responses suggested areas for further follow up that we intend to pursue through a Delphi-prioritization exercise. In order to operationalize the VBS, we will like greater clarity on what could constitute capacity building, the implications of the Nagoya Protocol on specimen sharing and how different countries have adopted benefit sharing recommendations [19]

The key features of the VBS would be its role as 'trusted broker' or "navigator" for guaranteeing the source of high-quality specimens for future pandemic threat agents, which includes the availability of granular information on the clinical phenotype linked to the sample and the potential of sequential samples over the course of the illness. The broker status also includes enhanced accessibility due to successful navigation of legal and logistics hurdles for which good examples already exist.

Another area of discussion is the use of the VBS as a source of specimens for reference 373 materials and panels. For example, one of the models considered for the VBS, is to request 374 specimen providers to identify and set aside a few large volume well-characterized high-375 guality specimens that can be accessed through the VBS, for use for in evaluation of 376 reference panels needed for calibration of diagnostics; this would require setting aside only a 377 portion of their respective collections rather than their entire biorepository or specimen 378 379 collection for a pathogen of interest. For this to happen, the local sites are responsible to ensure their local IRB approvals and informed consent processes clearly address the use of 380 the set-aside samples. About 40% of respondents indicated that they would consider setting 381 aside a small set of qualified specimens from their COVID-19 specimen collections for 382 383 sharing within the VBS. Most respondents indicated the need for follow up with more information. 384

385

386 Interviews with specimen consumers: identifying unmet needs and barriers to access

#### Revised version,11Jan2023. MChu

In the interviews, many of the participants from various types of organizations voiced the 387 hope that the features of the VBS would provide solutions to barriers identified, differing 388 389 primarily in ranking of priorities based on the types of organizations and their mission, such as small compared to large established diagnostics developers. The key features of this VBS 390 identified by all were: (a) serving as a trusted, reliable resource for identifying and accessing 391 392 characterized specimens and associated data and, (b) availability of characterized specimens of sufficient volume and quality fit for evaluation panels. Characterization of the 393 samples in a standardized process will have benefits partners especially in LMICs where 394 there is less opportunity to conduct the characterization themselves, thus providing them a 395 resource that could allow them to develop diagnostics locally for their specific market. An 396 example of potential benefit that the respondents agreed is a cross collaboration to create 397 398 clinical evaluation panels to validate and utilize for license submission for diagnostic test kits, especially where public health and test developers can provide access to clinically confirmed 399 400 case samples that would be difficult to assemble by a single entity, such as the comprehensive panel of sera from patients with various states of Lyme disease and healthy 401 402 persons .for Lyme disease serological diagnostic testing [23].

403

#### 404 **Comparison of local governance models**

The local governance models were driven by the idea of local management of specimens. In this case, the consortium representatives review all applications, but final decision making about sharing is still retained by the institution who has the local control of the specimens.

By promoting local biorepositories in LMICs, we offer technology transfer opportunities and capacity building even if dedicated funding cannot be guaranteed. We need to put emphasis on fit-for-purpose technologies appropriate for LMIC settings (lyophilized and dried stocks for example instead of low temp freezing). There needs to be high transparency standards because of the sensitivity of partners in LMICs about misuse of specimens. The focus on local biorepositories echoes the need expressed in the interviews for help with the operational challenges, including harmonized platforms and logistics.

This can be implemented by formal agreements between partners in the system, with the selection of partners based on willingness to adhere to the governance criteria (specimens,

Revised version,11Jan2023. MChu

- data, biorepository operations, MTA, sharing etc.). Such services will need constant
   monitoring, adapting to stakeholders and specifically user's needs.
- 419

#### 420 Limitations of this study

The survey was delayed from conception in 2019 to completion in 2021, interrupted by the 421 422 on-going COVID-19 pandemic. We made attempts to enroll all who had expressed interest 423 through our workshops to participate in our survey and interview on the concept of a VBS. All the respondents expressed interest in solving existing gaps for specimens' access, but not 424 everyone had a complete or in-depth understanding of all the issues around sharing or the 425 426 requirements of maintaining a non-centralized, federated biorepository. An outcome of this 427 first survey is to understand the type of engagement we might expect in a proposed VBS operation and we are actively pursuing steps to operationalize the proposed VBS. 428

429

#### 430 CONCLUSIONS

Biorepositories, as most in biological medical sciences professionals understand it, are 431 narrowly focused collected for research on specific conditions (cancer, precision medicine, 432 433 genetic and metabolic diseases, as examples) and more recently, for digital data. They typically require major investments in infrastructure and consistent long-term support, such 434 requirements have then relegated biorepositories to be primarily established in higher 435 income countries rather than countries with fewer resources where new pathogens may 436 emerge. A global unmet need has been access to quality specimens that represent the 437 diversity of where a disease "X" may yet emerge from. In the absence of specimens from 438 low resource settings, laboratory tests and vaccines may be developed without the 439 opportunity to fully assess their performance in all populations. 440

The vast spread of the COVID-19 pandemic and its duration has provided an abundance of specimens-- more than 100 sites identified by global search have identified themselves as COVID biobanks [1,14,16,20,24] but most have uncertain remit to what comes next-- thus this dilemma offers an excellent opportunity to address challenges for storage, access, sharing and sustainability.

#### Revised version,11Jan2023. MChu

In our study, we included the perspective of the 'clients' who are interested in high quality 446 specimens related to infections with outbreak potential. This allowed us from the specimen 447 collection perspective to examine the needs and identify the barriers in sourcing specimens 448 along with understanding the types of equitable benefits that participants themselves 449 positively identify as acceptable. We examined what might constitute a fair exchange 450 451 between the investigators collecting well-characterized specimens in LMIC and their clients; a system in which specimens of high value can be collected and replenished while benefits 452 of recognition and research participation activities can be fostered. 453

In recent years, recognizing the lack of access and knowledge of types of specimens, 454 455 multiple efforts have been set up to provide materials and have functioned successfully (EVA-G, ZIKAlliance, PATH, FIND) but they do not cover the entire spectrum of needs as 456 evident by multiple calls for better collections and sharing efforts [1,5,17], we think this is 457 where a VBS model could align and contribute. We especially recognize that there is a 458 need for well-annotated collection of serum/plasma from diverse geographical and disease 459 exposure experiences [14]. A focus on this type of specimens would allow us to build the 460 required infrastructure and activities of the VBS as proof of concept. 461

We also recognize some national laws and recommendations preclude exporting specimens but partners in those situations are open to collaborative research; we think then, depending on the research or project, diagnostic kits and protocols can be shared and shipped along with reference calibration materials to the site for evaluation thus allowing for active research collaboration.

467 Biorepositories are of many types and function [7,25-27]. Here we explicitly focus on their contribution to global preparedness by enabling and accelerating research and development 468 of interventions through rapid sharing of well annotated specimens to inform outbreak control 469 470 strategies. Specimen collection and storage would need to be distributed over a diverse 471 range of geography, ecozones, and demographics. Our idea of creating a distributed, grassroots biorepository is in alignment with concurrent efforts of the DxConnect and 472 modeled after the successful virus exchange by EVA-G [2]. Our effort through TGHN and 473 474 partnership with ZIKAlliance, ReCoDID and CREID allows us to fill in gaps in collections from 475 geographically diverse ecozones and human exposomes. A virtual biorepository that

#### Revised version,11Jan2023. MChu

functions as a trusted broker under a federated system on a demand-and-supply model 476 could allow many to participate without high costs. Such a system would also allow local 477 generators of biospecimens to receive benefits for setting aside potentially high value 478 specimens. Sets of well-characterized and richly annotated samples can be gueried in a 479 database under a common governance framework would allow contributors and users alike 480 481 to access materials respectfully as equal partners. Recent post-public health emergency epidemic reviews on lessons-learned for the future, all stated that preparedness must include 482 483 access to data and specimens [2,6,28-31], yet support for biorepository functions remain as an unfunded mandate for many so the recommended actions will need champions to 484 promote, socialize the benefits of specimen access and encourage investment in the sharing 485 systems. 486

487 In this paper, we present arguments for building a trusted sample sharing system based on a 488 distributed stewardship at the local level that manage the access to quality, wellcharacterized specimens for outbreak-prone infectious diseases as a global public good. 489 Accessing specimens, even within established networks and projects, remain highly 490 491 fragmented with procedures that often are not transparent and hampered by barriers leading to long lag time and can be very costly. We obtained knowledge, insights and advice through 492 493 our workshops, questionnaires, interviews and case examples from public health experts, 494 infectious disease researchers, biorepository managers, clinicians, policy makers, regulators, and especially diagnostic industry representatives to ascertain what might be appropriate 495 entry points to better organize fair and equitable sample sharing experience that allows more 496 497 engagement with source providers and stimulate research. The following challenges remain -(a) generating quality specimens, (b) overcoming barriers to accessing specimens 498 (regulatory, cost, sharing mechanisms), (c) generate a supportive exchange infrastructure, 499 (d) define benefit packages, and finally, (e) maintain trust between parties; all add up to 500 requiring the seeker of specimens to have persistence, commitment of precious time and 501 financial support as the outbreak of interest slips away and then only to repeat this cycle 502 again for the next outbreak. We propose a coordinated approach with logistics support and 503 assistance with procedures to facilitate exchange between sample providers and user. This 504 proposed system may work well and complement existing biorepositories efforts to provide 505

#### Revised version,11Jan2023. MChu

an alternate way to shorten the time to obtain results for decision making for preparednessand response to future public health emergencies.

508 We want to propose a solution that maintains respect for contributors and users of biological 509 materials. The concepts of equitable benefits sharing and capacity building are essential if 510 our effort is to be successful and long lasting. And finally, a coalition of the willing will be 511 needed to ensure funding, infrastructure and services to realize our vision. We look forward 512 to formalizing the framework and operationalize the VBS globally.

513

#### 514 Acknowledgements

515 The work was partially funded by the European Union Horizon 2020 Research and

516 Innovation Programme under Grant Agreement No. 825746, and is supported by the

517 Canadian Institutes of Health Research, Institute of Genetics (CIHR-IG) under Grant

Agreement No. 01886-000. We are indebted to FIND (Stefano Ongarello and Dominique

Allen) for co-sponsoring our first workshop and for joint discussions with PATH (Roger Peck

and Helen Storey) on the concept of the VBS. We are grateful to Zainab Al-Rawni, Adam

521 Dale and Trudie Lang of TGHN for hosting our VBS website and access to the workshops.

522

#### 523 Author Contributions

- 524 Conceptualization: Judith Giri, Thomas Jaenisch, May Chu,
- 525 Survey development and analysis: Judith Giri
- 526 Visualization: Judith Giri, Laura Pezzi, Rosa Margarita Gèlvez Ramirez, Rodrigo Cachay
- 527 Writing-original draft: Judith Giri, Thomas Jaenisch, May Chu
- 528 Writing- review and editing: All authors
- 529
- 530 **References**

Revised version,11Jan2023. MChu

- Croker JA, Patel R, Campbell KS, Barton-Baxter M, Wallet S, Firestein GS, et al.
   Building biorepositories in the midst of a pandemic. J Clin Transl Sci. 2021 Feb
   5;5(1):e92. doi: 10.1017/cts.2021.6.
- Coutard B, Romette JL, Miyauchi K, Charrel R, Prat CMA; EVA Zika Workgroup, EVA
   COVID-19 Workgroup. The importance of biobanking for response to pandemics
   caused by emerging viruses: The European Virus Archive as an observatory of the
   global response to Zika virus and COVID-19 Crisis. Biopreserv Biobank. 2020
   Dec;18(6):561-569. doi: 10.1089/bio.2020.0119.
- Peeling RW, Boeras D, Wilder-Smith A, Sall A, Nkengasong J. Need for sustainable
   biobanking networks for COVID-19 and other diseases of epidemic potential. Lancet
   Infect Dis. 2020 Oct;20(10):e268-e273. doi: 10.1016/S1473-3099(20)30461-8.
- Perkins MD, Dye C, Balasegaram M, Bréchot C, Mombouli JV, Røttingen JA, et al.
   Diagnostic preparedness for infectious disease outbreaks. Lancet. 2017 Nov
   11;390(10108):2211-2214. doi: 10.1016/S0140-6736(17)31224-2.
- 545 5. Mina MJ, Metcalf CJE, McDermott AB, Douek DC, Farrar J, Grenfell BT. A global
  546 immunological observatory to meet a time of pandemics. Elife. 2020 Jun 8;9:e58989.
  547 doi: 10.7554/eLife.58989.
- 548 6. World Health Organization. The WHO BioHub system-1 year progress report: May
  549 2021- May 2022. 2022 Jun 17;1:19. Available from:
- https://www.who.int/publications/m/item/who-biohub-system-1-year-progress-report may-2021-may-2022
- 552 7. DeSouza YG, Greenspan JS. Biobanking past, present and future: Responsibilities
  553 and benefits. AIDS. 2013 Jan 28;27(3):303-12. doi:

554 10.1097/QAD.0b013e32835c1244.

- Matzke LA, Tarling TE, Gali B, Dee S, LeBlanc J, Vercauteren S, et al. Finding the
   value in biobanks: Enhancing the CTRNet locator. Biopreserv Biobank. 2022
   Apr;20(2):132-137. doi: 10.1089/bio.2021.0043.
- Hewitt RE. Biobanking: The foundation of personalized medicine. Curr Opin Oncol.
   2011 Jan;23(1):112-9. doi: 10.1097/CCO.0b013e32834161b8.

Revised version,11Jan2023. MChu

560	10. Vaught J, Kelly A, Hewitt R. A review of international biobanks and networks: Success
561	factors and key benchmarks. Biopreserv Biobank. 2009 Sep;7(3):143-50. doi:
562	10.1089/bio.2010.0003.
563	11.Campbell LD, Astrin JJ, DeSouza Y, Giri J, Patel AA, Rawley-Payne M, et al. The
564	2018 Revision of the ISBER Best Practices: Summary of Changes and the Editorial
565	Team's Development Process. Biopreserv Biobank. 2018 Feb;16(1):3-6. doi:
566	10.1089/bio.2018.0001.
567	12. Coppola L, Cianflone A, Grimaldi AM, Incoronato M, Bevilacqua P, Messina F, et al.
568	Biobanking in healthcare: Evolution and future directions. J Transl Med. 2019 May
569	22;17(1):172. doi: 10.1186/s12967-019-1922-3.
570	13. Klingler C, von Jagwitz-Biegnitz M, Hartung ML, Hummel M, Specht C. Evaluating the
571	German Biobank Node as coordinating institution of the German Biobank Alliance:
572	Engaging with stakeholders via survey research. Biopreserv Biobank. 2020
573	Apr;18(2):64-72. doi: 10.1089/bio.2019.0060.
574	14. Colella JP, Bates J, Burneo SF, Camacho MA, Carrion Bonilla C, Constable I, et al.
575	Leveraging natural history biorepositories as a global, decentralized, pathogen
576	surveillance network. PLoS Pathog. 2021 Jun 3;17(6):e1009583. doi:
577	10.1371/journal.ppat.1009583.
578	15. Golden A, Cantera JL, Lillis L, Phan TT, Slater H, Webb EJ, et al. A reagent and virus
579	benchmarking panel for a uniform analytical performance assessment of N antigen-
580	based diagnostic tests for COVID-19. medRxiv 2022.08.03.22278351 [Preprint]. 2022
581	[cited 2022 Dec 30]. Available from:
582	https://www.medrxiv.org/content/10.1101/2022.08.03.22278351v1 doi:
583	https://doi.org/10.1101/2022.08.03.22278351
584	16.LaVergne SM, Stromberg S, Baxter BA, Webb TL, Dutt TS, Berry K, et al. A
585	longitudinal SARS-CoV-2 biorepository for COVID-19 survivors with and without post-
586	acute sequelae. BMC Infect Dis. 2021 Jul 13;21(1):677. doi: 10.1186/s12879-021-
587	06359-2.
588	17. Metcalf CJ, Farrar J, Cutts FT, Basta NE, Graham AL, Lessler J, et al. Use of
589	serological surveys to generate key insights into the changing global landscape of

Revised version,11Jan2023. MChu

- infectious disease. Lancet. 2016 Aug 13;388(10045):728-30. doi: 10.1016/S0140 6736(16)30164-7.
- 18. Romette JL, Prat CM, Gould EA, de Lamballerie X, Charrel R, Coutard B, et al. The
  European Virus Archive goes global: A growing resource for research. Antiviral Res.
  2018 Oct;158:127-134. doi: 10.1016/j.antiviral.2018.07.017.
- 19. Heinrich M, Scotti F, Andrade-Cetto A, Berger-Gonzalez M, Echeverría J, Friso F, et
  al. Access and benefit sharing under the Nagoya Protocol- *Quo Vadis?* Six Latin
  American case studies assessing opportunities and risk. Front Pharmacol. 2020 Jun
  8;11:765. doi: 10.3389/fphar.2020.00765.
- 20. Kamulegeya R, Kateete DP, Bagaya BS, Nasinghe E, Muttamba W, Nsubuga G, et al.
  Biobanking: Strengthening Uganda's rapid response to COVID-19 and other
  epidemics. Biopreserv Biobank. 2022 Jun;20(3):238-243. doi: 10.1089/bio.2021.0022.
- 21. Avelino-Silva VI, Mayaud P, Tami A, Miranda MC, Rosenberger KD, Alexander N, et
  al. Study protocol for the multicentre cohorts of Zika virus infection in pregnant
  women, infants, and acute clinical cases in Latin America and the Caribbean: the
  ZIKAlliance consortium. BMC Infect Dis. 2019 Dec 26;19(1):1081. doi:
  10.1186/s12879-019-4685-9.
- 607 22. Michell, R. 202 rankings of the world's largest IVD corporations. Dark Report
  608 [internet]. 2021 Sep 7;28(12). Available from:
- 609 <u>https://www.darkintelligencegroup.com/the-dark-report/in-vitro-diagnostics/2020-</u> 610 rankings-of-the-worlds-largest-ivd-corporations/.
- 23. Molins CR, Sexton C, Young JW, Ashton LV, Pappert R, Beard CB, et al. Collection
   and characterization of samples for establishment of a serum repository for Lyme
   disease diagnostic test development and evaluation. J Clin Microbiol. 2014
   Oct;52(10):3755-62. doi: 10.1128/JCM.01409-14.
- 24. Burke H, Freeman A, Dushianthan A, Celinski M, Batchelor J, Phan H, et al. Research
  Evaluation Alongside Clinical Treatment in COVID-19 (REACT COVID-19): an
  observational and biobanking study. BMJ Open. 2021 Jan 22;11(1):e043012. doi:
  10.1136/bmjopen-2020-043012.
- 25. Holub P, Kohlmayer F, Prasser F, Mayrhofer MT, Schlünder I, Martin GM, et al.
   Enhancing reuse of data and biological material in medical research: From FAIR to

Revised version,11Jan2023. MChu

- 621 FAIR-Health. Biopreserv Biobank. 2018 Apr;16(2):97-105. doi:
- 622 10.1089/bio.2017.0110.
- 26. Mendy M, Lawlor RT, van Kappel AL, Riegman PHJ, Betsou F, Cohen OD, et al.
  Biospecimens and biobanking in global health. Clin Lab Med. 2018 Mar;38(1):183207. doi: 10.1016/j.cll.2017.10.015.
- 27. Vaught J, Lockhart N. The evolution of biobanking best practices Clin Chim Acta.
  2012 Oct 9;413(19-20):1569-75. doi: 10.1016/j.cca.2012.04.030.
- 28. Haselbeck AH, Im J, Prifti K, Marks F, Holm M, Zelleger RM. Serology as a tool to
  assess infectious diseases landscaped and guide public health policy. Pathogens.
  2022 Jun 27:11(7):732. doi: 10.3390/pathogens11070732.
- 29. Wilder-Smith A, Lindsay SW, Scott TW, Ooi EE, Gubler DJ, Das P. The Lancet
  Commission on dengue and other *Aedes*-transmitted viral diseases. Lancet. 2020
  Jun 20;395(10241):1890-1891. doi: 10.1016/S0140-6736(20)31375-1.
- 30. Moon S, Sridhar D, Pate MA, Jha AK, Clinton C, Delaunay S, et al. Will Ebola change
  the game? Ten essential reforms before the next pandemic. The report of the
  Harvard-LSHTM Independent Panel on the Global Response to Ebola. Lancet. 2015
  Nov 28;386(10009):2204-21. doi: 10.1016/S0140-6736(15)00946-0.
- 31. Sachs JD, Karim SSA, Aknin L, Allen J, Brosbøl K, Colombo F, et al. The Lancet
  Commission on lessons for the future from the COVID-19 pandemic. Lancet. 2022
  Oct 8;400(10359):1224-1280. doi: 10.1016/S0140-6736(22)01585-9.

641

Revised version,11Jan2023. MChu

#### 643 SUPPORTIVE INFORMATION (SI): Figures and Tables

## 644 Figures

- 645 SI, Figure 1. Logistical diagrams on the governance of locally managed biorepositories
- 646 Figure 1A: The Industrial University of Santander, Bucamaranga, Colombia and the Fundación
- 647 INFOVIDA and Centro de Atención y Diagnóstico de Enfermedades Infecciosas-C
- 648 Figure 1B: Cayetano Heredia University, Lima, Peru
- 649 Figure 1C: University of Carabobo, Valencia, Venezuela
- 650

#### 651 **TABLES**

#### 652 **SI, Table 1**

Table 1: Virtual Biorepository (VBR) Benefits Questionnaire			
CATEGORY	QUESTIONS		
Profile of respondents	1. What is the nature of your institution		
	2. What is your role		
	3. What is your geographic location		
Benefits of participation:	4. Which planned VBR benefits would be most important to		
support functions and	you/your institution?		
resources			
	5. Which VBR support functions would be most valuable to your		
	current biorepository or collection?		
	6. Which additional resources would allow you to participate in the		
	VBR?		
Benefit sharing and the	7. Does your country have a specific policy in accord with the NP?		
Nagoya protocol			
	<ul> <li>If yes, would it prevent you from sharing specimens outside</li> </ul>		
	the country?		
	- If yes, would you be willing to test in country?		

Revised version,11Jan2023. MChu

Interest in participation	8. Would you be interested in participating in a VBR
Contributing to reference	9. Would you be willing to set aside limited numbers of samples for
material and panels	use as reference materials and as part of evaluation panels?
Other benefits?	10. Comments

653

#### 654 SI, Table 2. Interviews to assess needs and barriers to accessing specimens

# What are your greatest hurdles for access to specimens? Examples of issues to consider: identifying sources; reliability of sources; cost; quality of specimens; completeness and reliability of accompanying data; legal hurdles: Material Transfer Agreements (MTA) and negotiations; other What are your current strategies for access? What type of specimens have been difficult to source for COVID/19 and other infectious diseases? What are some of the challenges for access to specimens in LMICs? S. Which features of a Virtual Biorepository would be most useful? VB features to consider: coordinated, one stop access to specimens; an online catalog or directory of sources; more affordable specimen sources; trusted source of qualified specimens; facilitated access including MTA negotiations and logistics; other 6. Would you be willing to contribute to creation of a manufacturer's panel <sup>(1</sup> 7.Do you have any additional comments and recommendations?

655

656

657 SI, Table 3

Table 3. Interview summary of gaps and barriers to access			
Grouping	Commercial Diagnostics Developers	Not-for-profit	

Revised version,11Jan2023. MChu

	Small scale* IVD	High volume** IVD	Specimen	Public Health/
	companies	companies	providers and	government
			services	collaborations
Access to specimen strategies	<ul> <li>Commercial specimen supplier</li> <li>Government/ academic collaborations</li> </ul>	<ul> <li>Established collaborations, with long term agreements</li> <li>Use some commercial sources (via NGOs in LMICs)</li> </ul>	Collaborations and partnerships	Asking other laboratories/ academic networks
Greatest barriers to access ***	<ul> <li>Identifying reliable sources/timely access</li> <li>Quality and quantity of specimens</li> <li>Access to data and quality of data</li> </ul>	<ul> <li>Quality of specimens</li> <li>Access to complete accompanying data</li> <li>Data access restrictions (Europe)</li> </ul>	<ul> <li>complete accompanying data, especially for specimens left over from testing</li> <li>Pathogen characterization/ sequence data</li> <li>Legal negotiations</li> </ul>	<ul> <li>Access to specimen sources</li> <li>Access to clinical data (where/when specimens were collected)</li> <li>Timely access</li> </ul>
Availability of specific specimen types (COVID-19 and other)***	<ul> <li>Timely availability early in an outbreak/epidemic</li> <li>Limited availability of non-COVID 19 specimens (seasonal, geographic, etc.,)</li> <li>COVID-19: swabs, virus, longitudinal samples</li> </ul>	Access to specimen types needed for development	<ul> <li>Scarcity of specimen types needed at different stages of an outbreak or epidemic and diseases other than COVID-19</li> <li>Access to clinical trial specimens</li> </ul>	<ul> <li>Specific types needed based on pathogen and stage of outbreak;</li> <li>Peripheral blood mononuclear</li> <li>Longitudinal samples</li> </ul>
Gap for IVD quality assessment ***	<ul> <li>Panels and reference materials</li> <li>Panels to meet regulatory requirements</li> </ul>	Panels and reference materials	Panels and reference materials	Panels and reference materials
Access to specimens in LMICs***	Not often, through desired. Not enough resources	Differences in country regulations (e.g., Nagoya protocol) regarding sharing and biosafety	Difficulties in both exporting and importing specimens	<ul> <li>Biosafety and security restrictions</li> <li>Infrastructure needed to maintain quality and safety</li> </ul>
VBR solutions – features of VBR to facilitate access	<ul> <li>Directory</li> <li>Coordinate a one- stop, trusted resource</li> <li>Accelerating access: logistics, negotiations, etc.</li> <li>Access to rare - disease specimens</li> </ul>	<ul> <li>Access to well characterized specimens</li> <li>Access to complete specimen- associated data</li> <li>Trusted resource to accelerate development path and approval by regulatory authority</li> <li>Access to a directory of sources</li> </ul>	<ul> <li>Both groups in the not-for profit category identified same benefits</li> <li>Access to sufficient volumes for panels</li> <li>Standardized templates for agreements</li> <li>Harmonization of initiatives and standardized vocabulary</li> <li>Responsive to needs of stakeholders/users of specimens</li> <li>Governance: based on local ownership and equal partnerships</li> <li>Building trust through quality</li> <li>Benefits and capacity building in LMICs (training, other resources)</li> <li>Access to well characterized and well annotated specimens</li> </ul>	

Revised version,11Jan2023. MChu

- <sup>658</sup> \*Small scale companies are ones that sell 10 or less IVD products with sales of less than 1% of IVD market
- \*\*Large volume producers with over greater than 10 IVD products and sales of over 10% of IVD market(Michell)
- <sup>\*\*\*</sup> Types of barriers that delay and preclude accurate and timely test development-to-market timeline

# TITLE: Specimens sharing for epidemic preparedness: building a virtual biorepository system from local governance to global partnerships

Authors:

```
Judith Giri<sup>1&</sup>, Laura Pezzi<sup>2^</sup>, Rodrigo Cachay<sup>3^</sup>, Rosa Margarita Gèlvez Ramirez<sup>4^</sup>,
Adirana Tami<sup>#5<sup>*</sup></sup>, Sarah Bethencourt<sup>6<sup>*</sup></sup>, Anylea Lozano<sup>7<sup>*</sup></sup>, Julia Poje<sup>1<sup>*</sup></sup>, Thomas
Jaenisch<sup>1&</sup>, May Chu<sup>1&*</sup>
```

medRxiv preprint doi: https://doi.org/11./191/2022.04/17.23284/660; this variation posted January 18, 2023. The copyright holder for this preprint (which was no certified by peer review) is the aution/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

# Figures





Figure 1: The geographic location of survey respondents


# Figure 2. Governance structure of the ZIKAlliance local biorepositories




Supportive Information Figure

# SI, Figure 1. Logistical diagrams on the governance of locally managed biorepositories


Figure 1A: The Industrial University of Santander, Bucamaranga, Colombia and the Fundación INFOVIDA and Centro de Atención y Diagnóstico de Enfermedades Infecciosas-CDI.







IMTAvH: Instituto de Medicina Tropical Alexander von Humbolt



# Figure 1C: University of Carabobo, Valencia, Venezuela